Cover Image

The Role and Mechanisms of Aurora Kinases in Kidney Diseases

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Meiying Chang, Qiuyi Li, Zhenwei Shi, Shougang Zhuang
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Clinical Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level
by: Junghyun Cho, et al.
Published: (2024)

Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
by: Pamela Navarro‐Gonzales, et al.
Published: (2024)

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes
by: Shih‐Hsuan Lin, et al.
Published: (2026)

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
Published: (2024)

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis
by: Fan Huang, et al.
Published: (2024)

Changes in Protein Expression of Renal Drug Transporters and Drug‐Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients
by: Annika C. Tillmann, et al.
Published: (2025)

BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase
by: Aurélie Cabannes‐Hamy, et al.
Published: (2025)

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis
by: Antonio Tursi, et al.
Published: (2026)

Extracellular Vesicles as Immunotherapeutic Mediators in Gastrointestinal Cancers and Diseases: From Mechanisms to Clinical Translation
by: Xiaona Lin, et al.
Published: (2026)

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
by: Yi‐An Bi, et al.
Published: (2024)

Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
by: Tania Payo‐Serafín, et al.
Published: (2024)

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV : An Emerging Frontier for Clinical Pharmacology
by: Aaron S. Devanathan, et al.
Published: (2025)

Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury
by: Sushrut S. Waikar, et al.
Published: (2025)

Prediction of the Intra‐T Lymphocyte Tacrolimus Concentration after Kidney Transplantation with Population Pharmacokinetic Modeling
by: Suwasin Udomkarnjananun, et al.
Published: (2024)

Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
by: Wenqi Dong, et al.
Published: (2025)

Predicting OCT2 / MATEs ‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)
by: Satoshi Asano, et al.
Published: (2025)

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review
by: Wafa Alatawi, et al.
Published: (2025)

Sex and the Kidney Drug‐Metabolizing Enzymes and Transporters: Are Preclinical Drug Disposition Data Translatable to Humans?
by: Aarzoo Thakur, et al.
Published: (2024)

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development
by: Tanja S. Zabka, et al.
Published: (2025)

Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation
by: Lukas K. van Vugt, et al.
Published: (2025)

Better Rejection‐Free Survival at Three Years in Kidney Transplant Recipients With Model‐Informed Precision Dosing of Mycophenolate Mofetil
by: Claire Villeneuve, et al.
Published: (2024)

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data
by: Michael I. Sponfeldner, et al.
Published: (2025)

A Systematic Review of the Costs of Drug‐Associated Acute Kidney Injury and Potential Cost Savings With Nephrotoxin Stewardship Prevention Strategies
by: Britney A. Stottlemyer, et al.
Published: (2024)

Pseudo‐Worsening of Kidney Function Due to Inhibition of Renal Creatinine Secretion: Quality of Information Provided in Prescribing Information/SmPC
by: Michael I. Sponfeldner, et al.
Published: (2024)

MRI Provides New Insights Into the Pharmacologic Mechanism of Bisacodyl: A Blueprint for Understanding Intestinal Drug Mechanisms
by: Kathleen M. Giacomini
Published: (2025)

The Role for Clinical Translational Pharmacology in Advancing Pharmacoequity
by: Sonya Tang Girdwood, et al.
Published: (2025)

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5 *6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients
by: Amar D. Levens, et al.
Published: (2025)

Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study
by: Jieni Li, et al.
Published: (2024)

B‐ and T‐Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis
by: Andrew C. Vendel, et al.
Published: (2024)

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
by: Pepijn P.N.M. Eijsvogel, et al.
Published: (2026)

Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers
by: Mariam A. Ahmed, et al.
Published: (2024)

The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making
by: Mary Summer Starling, et al.
Published: (2024)

Exposure‐Response Relationships for Axatilimab in Patients with Chronic Graft‐Versus‐Host Disease
by: Yan‐ou Yang, et al.
Published: (2025)

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
by: Amitava Mitra, et al.
Published: (2024)

Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
by: Sumit Bhatnagar, et al.
Published: (2024)

Impact of Chronic Inflammatory Diseases on Clinical Pharmacokinetics of Antibody‐Based Therapeutic Proteins
by: Xiaofan Tian, et al.
Published: (2024)

Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study
by: Teng‐Li Lin, et al.
Published: (2026)

Rare Diseases Linked to Mutations in Vitamin Transporters Expressed in the Human Blood–Brain Barrier
by: Sook Wah Yee, et al.
Published: (2024)

Effects of Sacubitril/Valsartan on Survival in Patients with Heart Failure and Significant Valvular Heart Disease
by: Donna Shu‐Han Lin, et al.
Published: (2024)

The Promise of Health for All: A Collaborative Model to Close Treatment Gaps for Neglected Diseases
by: Delali Attipoe
Published: (2024)